Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $31.28 USD
Change Today +2.94 / 10.37%
Volume 6.7M
MDCO On Other Exchanges
Symbol
Exchange
NASDAQ GS
As of 8:10 PM 07/2/15 All times are local (Market data is delayed by at least 15 minutes).
text size: T | T
Back to Snapshot
Company Description

Contact Info

8 Sylvan Way

Parsippany, NJ 07054

United States

Phone: 973-290-6000

Fax: 973-656-9898

The Medicines Company operates as a biopharmaceutical company. Products The company markets Angiomax (bivalirudin), Cleviprex (clevidipine) injectable emulsion, Minocin (minocycline) for injection, Orbactiv (oritavancin), PreveLeak, and Recothrom Thrombin topical (Recombinant). The company also has a pipeline of acute and intensive care hospital products in development, including four registration stage product candidates for which the company has submitted applications for regulatory approval in the United States, cangrelor, IONSYS (fentanyl iontophoretic transdermal system), Raplixa, and RPX-602; and four research and development product candidates, ABP-700, ALN-PCSsc, Carbavance and MDCO-216. The company has the right to develop, manufacture and commercialize ALN-PCSsc under its collaboration agreement with Alnylam Pharmaceuticals, Inc. (Alnylam). In addition to these products and products in development, the company sells a ready-to-use formulation of Argatroban and has a portfolio of 10 generic drugs, which the company refers to as its acute care generic products, that the company has the non-exclusive right to market in the United States. The company sells three of its acute care generic products, midazolam, ondansetron and rocuronium. Marketed Products Angiomax Angiomax is an intravenous direct thrombin inhibitor that is a peptide compound. The company has exclusive license rights to develop, market, and sell Angiomax worldwide. Angiomax is approved in the United States for use as an anticoagulant in combination with aspirin in patients with unstable angina undergoing percutaneous transluminal coronary angioplasty (PTCA) and for patients undergoing percutaneous coronary intervention (PCI), with provisional use of glycoprotein IIb/IIIa receptor inhibitors, or GP IIb/IIIa inhibitors, including patients with or at risk of HIT/HITTS. Angiomax is approved in the European Union for use as an anticoagulant in adult patients undergoing PCI, including patients with STEMI undergoing primary PCI. The approval for acute coronary syndrome (ACS) in Europe also includes treatment of adult patients with unstable angina or non-STEMI planned for urgent or early intervention, when used with aspirin and clopidogrel. In Europe, the company markets Angiomax under the tradename Angiox. Angiomax is also approved for use in Australia, Canada, New Zealand, Russia, India and other countries in Central America, South America and the Middle East for PCI indications similar to those approved by the Food and Drug Administration (FDA) or European Medicines Agency (EMA). In addition, Angiomax is approved in Canada for the treatment of patients with HIT/HITTS undergoing cardiac surgery. Cleviprex Cleviprex is an intravenous small molecule calcium channel blocker. The company licensed Cleviprex from AstraZeneca AB in 2003 and has exclusive license rights to develop, market, and sell Cleviprex worldwide. In addition to the United States, the new formulation of Cleviprex is approved for sale in Australia, Austria, Belgium, Canada, France, Germany, Liechtenstein, Luxembourg, the Netherlands, Spain, Sweden, Switzerland and the United Kingdom with various indications, including for short term treatment of hypertension when oral therapy is not feasible or desirable in Australia, for management of acute elevation of blood pressure in perioperative settings in Canada, and for the rapid reduction of blood pressure in perioperative settings in the European Union and Switzerland. Minocin IV Minocin IV is an intravenous formulation of a tetracycline-class antibiotic that is approved in the United States for the treatment of infections due to susceptible strains of designated gram-negative bacteria, including those due to Acinetobacter spp, and designated gram-positive bacteria. Minocin IV is also approved for the treatment of infections caused by the following microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: skin and skin structure infections caused by Staphylococcus aureus, Escherichia coli, Enterobacter aerogenes. Shigella species, respiratory tract infections caused by Haemoph

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
MDCO:US $31.28 USD +2.94

MDCO Competitors

Market data is delayed at least 15 minutes.

Company Last Change
BTG PLC 669.00 GBp -17.00
Impax Laboratories Inc $46.31 USD -0.34
Integra LifeSciences Holdings Corp $60.53 USD +0.63
Krka dd Novo mesto €65.00 EUR 0.00
Richter Gedeon Nyrt 4,172 -58.00
View Industry Companies
 

Industry Analysis

MDCO

Industry Average

Valuation MDCO Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 3.0x
Price/Book 2.0x
Price/Cash Flow NM Not Meaningful
TEV/Sales 1.3x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact MEDICINES COMPANY, please visit www.themedicinescompany.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.